Sutro Biopharma (STRO) Equity Average (2018 - 2025)

Sutro Biopharma has disclosed Equity Average across 8 years of filings, most recently posting -$109.9 million for Q4 2025.

• Equity Average for Q4 2025 came in at -$109.9 million, down 241.01% year-over-year; the trailing twelve-month figure through Dec 2025 was -$109.9 million (down 241.01% YoY), and the FY2025 annual result was -$43.9 million, down 145.23% from the prior year.
• Equity Average came in at -$109.9 million for Q4 2025 at Sutro Biopharma, down from -$59.7 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $319.7 million in Q1 2021 to a low of -$109.9 million in Q4 2025.
• The 5-year median for Equity Average is $151.8 million (2023), against an average of $149.5 million.
• Across the five-year window, Equity Average surged 255.46% in 2021 and plunged 241.01% in 2025, its largest moves.
• Sutro Biopharma's Equity Average stood at $268.1 million in 2021, then dropped by 16.67% to $223.4 million in 2022, then slumped by 41.34% to $131.0 million in 2023, then plunged by 40.54% to $77.9 million in 2024, then slumped by 241.01% to -$109.9 million in 2025.
• The last three Equity Average figures came in at -$109.9 million (Q4 2025), -$59.7 million (Q3 2025), and -$29.0 million (Q2 2025), per Business Quant data.